MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
EyePoint Pharmaceuticals General and Administrative Expenses 2011-2026 | EYPT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses EyePoint Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.6 M | 52.4 M | 40.1 M | 34.8 M | 25.6 M | 20.7 M | 17.9 M | 11.5 M | 11.2 M | 9.01 M | 8.06 M | 7.47 M | 7.17 M | 6.87 M | 8.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52.4 M | 6.87 M | 20.8 M |
Quarterly General and Administrative Expenses EyePoint Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.5 M | 11.9 M | 13.9 M | - | 13 M | 12.8 M | 14.1 M | - | 10.6 M | 9.06 M | 9.24 M | - | 9.21 M | 8.56 M | 8.55 M | - | 6.06 M | 5.18 M | 5.12 M | - | 5.8 M | 4.79 M | 4.36 M | - | 4.36 M | 4.82 M | 4.61 M | - | 4.16 M | 4.22 M | 4.16 M | 2.47 M | 2.57 M | 5.04 M | 2.57 M | 2.9 M | 3.28 M | 2.9 M | 3.28 M | 2.04 M | 1.97 M | 2.04 M | 1.97 M | 1.87 M | 1.73 M | 1.87 M | 1.73 M | 1.71 M | 1.81 M | 1.71 M | 1.81 M | 1.66 M | 1.62 M | 1.66 M | 1.62 M | 1.45 M | 2.06 M | 1.45 M | 2.06 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 M | 1.45 M | 4.88 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Esperion Therapeutics
ESPR
|
166 M | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
519 M | $ 48.2 | 8.51 % | $ 13.1 B | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Fortress Biotech
FBIO
|
96.4 M | $ 2.53 | 2.85 % | $ 70.6 M | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
141 M | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |
 |
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | USA |
 |
Genmab A/S
GMAB
|
661 M | $ 27.95 | 1.5 % | $ 17.2 B |  Danmark |
 |
Genprex
GNPX
|
6.09 M | $ 0.91 | 2.24 % | $ 849 K | USA |
 |
Grifols, S.A.
GRFS
|
1.06 B | $ 8.4 | 1.63 % | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
12 M | $ 2.51 | 27.16 % | $ 152 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
394 M | $ 77.0 | 2.33 % | $ 12.3 B | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 94.64 | -0.9 % | $ 27.2 B | Germany |
 |
Kamada Ltd.
KMDA
|
12.6 M | $ 8.29 | 0.91 % | $ 260 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
68.2 M | $ 85.79 | 3.72 % | $ 7.25 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
4.51 M | $ 13.58 | 0.97 % | $ 1.8 B |  Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
78.7 M | $ 231.58 | -0.31 % | $ 4.24 B | USA |
 |
INmune Bio
INMB
|
10.3 M | $ 1.54 | - | $ 38.1 M | USA |
 |
Liquidia Corporation
LQDA
|
157 M | $ 41.64 | 3.75 % | $ 3.58 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
488 M | $ 22.58 | 1.03 % | $ 3.74 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
257 M | $ 107.36 | 1.46 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
144 M | $ 3.61 | 26.17 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.46 | -1.14 % | $ 5.7 M | Israel |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 24.0 | 2.46 % | $ 3.05 B | USA |
 |
Nanobiotix S.A.
NBTX
|
19.4 M | $ 41.6 | 19.64 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |